Stocks and InvestingStocks and Investing
Tue, March 15, 2022
Mon, March 14, 2022
Fri, March 11, 2022
Thu, March 10, 2022

Charles Duncan Maintained (ACAD) at Buy with Increased Target to $37 on, Mar 10th, 2022


Published on 2024-10-27 20:02:33 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $32 to $37 on, Mar 10th, 2022.

Charles has made no other calls on ACAD in the last 4 months.



There are 11 other peers that have a rating on ACAD. Out of the 11 peers that are also analyzing ACAD, 7 agree with Charles's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Decreased Target to $24 on, Monday, March 7th, 2022
  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $28 on, Thursday, March 3rd, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $30 on, Wednesday, December 22nd, 2021
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021


These are the ratings of the 4 analyists that currently disagree with Charles


  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022
  • Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $36 on, Wednesday, February 9th, 2022
  • Neena Bitritto-Garg of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $30 on, Wednesday, January 5th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021